Dec 7, 2020 | News, Press Releases
Cognitive-behavioral conjoint therapy (CBCT) for posttraumatic stress disorder (PTSD), when combined with MDMA, resulted in significant improvements in PTSD symptoms Six couples, in which one partner was diagnosed with PTSD, participated in a seven-week protocol; both...Dec 2, 2020 | News, Press Releases
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support...Nov 24, 2020 | News, Press Releases
Pilot study explored the application of MDMA-assisted psychotherapy in 18 individuals experiencing moderate to severe anxiety following diagnosis with a life-threatening illness The primary outcome, change in State-Trait Anxiety Inventory (STAI) Trait Scores,...Oct 14, 2020 | News, Press Releases
Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients Santa Cruz, CA, October 14, 2020 – A peer-reviewed study published today in the research journal...Jul 8, 2020 | News, Press Releases
MAPS Public Benefit Corporation (MAPS PBC) welcomes Jason Pyle, an experienced CEO and executive leader, to their Board of Directors. A wholly-owned subsidiary of the Multidisciplinary Association of Psychedelic Studies (MAPS), MAPS PBC catalyzes healing and...Jun 10, 2020 | News, Press Releases
MEDIA CONTACT:Brad Burge, Director of Strategic Communications, MAPSbrad@maps.org GENERAL QUESTIONS:AskMAPS@maps.org Today, the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) announced the publication of the long-term follow-up results of six...